{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:39:07Z","timestamp":1770748747317,"version":"3.50.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"AGAUR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.neo.2025.101131","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:42:55Z","timestamp":1738716175000},"page":"101131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2Y641mut germinal center-derived lymphoma"],"prefix":"10.1016","volume":"61","author":[{"given":"Ar\u00e1nzazu","family":"Chamorro-Jorganes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Profit\u00f3s-Pelej\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5039-3274","authenticated-orcid":false,"given":"Clara","family":"Recasens-Zorzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3193-9099","authenticated-orcid":false,"given":"Juan G","family":"Valero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Reyes-Garau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Magnano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2847-3673","authenticated-orcid":false,"given":"Ray","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Postigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"P\u00e9rez-Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo Lima","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-2257","authenticated-orcid":false,"given":"Ga\u00ebl","family":"Rou\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2025.101131_bib0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrg3607","article-title":"Chromatin modifiers and remodellers: regulators of cellular differentiation","volume":"15","author":"Chen","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.neo.2025.101131_bib0002","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neo.2025.101131_bib0003","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neo.2025.101131_bib0004","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/eji.200424985","article-title":"Distinct expression patterns of polycomb oncoproteins and their binding partners during the germinal center reaction","volume":"34","author":"van Galen","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.neo.2025.101131_bib0005","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1182\/blood-2010-04-280149","article-title":"EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis","volume":"116","author":"Velichutina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.neo.2025.101131_bib0006","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccr.2012.09.003","article-title":"Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas","volume":"22","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2025.101131_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028585","article-title":"EZH2 Codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas","volume":"6","author":"Ryan","year":"2011","journal-title":"PLoS. One"},{"key":"10.1016\/j.neo.2025.101131_bib0008","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1038\/leu.2013.94","article-title":"Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity","volume":"27","author":"Zhao","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2025.101131_bib0009","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1182\/blood-2012-12-473439","article-title":"A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis","volume":"123","author":"Berg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.neo.2025.101131_bib0010","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/1535-7163.MCT-15-0750","article-title":"BRD4 regulates EZH2 transcription through upregulation of C-MYC and represents a novel therapeutic target in bladder cancer","volume":"15","author":"Wu","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neo.2025.101131_bib0011","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.neo.2025.101131_bib0012","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.chembiol.2013.09.013","article-title":"Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth","volume":"20","author":"Garapaty-Rao","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.neo.2025.101131_bib0013","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1016\/j.bmcl.2015.06.056","article-title":"Discovery, design, and synthesis of indole-based EZH2 inhibitors","volume":"25","author":"Gehling","year":"2015","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.neo.2025.101131_bib0014","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/ijms23010253","article-title":"Histone modifications and their targeting in lymphoid malignancies","volume":"23","author":"Fern\u00e1ndez-Serrano","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neo.2025.101131_bib0015","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-20-2147","article-title":"EZH2-targeted therapies in cancer: hype or a reality","volume":"80","author":"Eich","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101131_bib0016","article-title":"Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma","volume":"104","author":"Recasens-Zorzo","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.neo.2025.101131_bib0017","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.3324\/haematol.2017.164632","article-title":"The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of ikaros and MYC signaling","volume":"102","author":"D\u00edaz","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.neo.2025.101131_bib0018","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/leu.2014.106","article-title":"Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma","volume":"28","author":"Moros","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2025.101131_bib0019","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/blood-2008-03-147645","article-title":"MYC stimulates EZH2 expression by repression of its negative regulator miR-26a","volume":"112","author":"Sander","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.neo.2025.101131_bib0020","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1158\/1078-0432.CCR-14-0154","article-title":"Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (buparlisib)","volume":"20","author":"Matas-C\u00e9spedes","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2025.101131_bib0021","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 Is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"B\u00e9guelin","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2025.101131_bib0022","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1073\/pnas.1210371110","article-title":"Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation","volume":"109","author":"Qi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.neo.2025.101131_bib0023","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","article-title":"EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity","volume":"121","author":"Yan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.neo.2025.101131_bib0024","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.3324\/haematol.2020.278258","article-title":"Interleukin-1 receptor associated kinase 1\/4 and bromodomain and extra-terminal inhibitions converge on NF-\u03bab blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation","volume":"106","author":"Dlouhy","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.neo.2025.101131_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2019.00986","article-title":"Recent advances in the targeting of epigenetic regulators in b-cell non-hodgkin lymphoma","volume":"10","author":"Ribeiro","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.neo.2025.101131_bib0026","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1158\/1535-7163.MCT-16-0297","article-title":"Identification of pharmacodynamic transcript biomarkers in response to FGFR inhibition by AZD4547","volume":"15","author":"Delpuech","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neo.2025.101131_bib0027","doi-asserted-by":"crossref","first-page":"7591","DOI":"10.2147\/OTT.S222223","article-title":"GADD45a mediated cell cycle inhibition is regulated by p53 in bladder cancer","volume":"12","author":"Han","year":"2019","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.neo.2025.101131_bib0028","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1006\/excr.2000.4906","article-title":"The central region of Gadd45 is required for its interaction with p21\/WAF1","volume":"258","author":"Zhao","year":"2000","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.neo.2025.101131_bib0029","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"B\u00f6d\u00f6r","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.neo.2025.101131_bib0030","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1021\/acs.jmedchem.6b01315","volume":"59","author":"Vaswani","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neo.2025.101131_bib0031","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neo.2025.101131_bib0032","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.neo.2025.101131_bib0033","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.4049\/jimmunol.1400839","article-title":"Gene targeting RhoA reveals its essential role in coordinating mitochondrial function and thymocyte development","volume":"193","author":"Zhang","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.neo.2025.101131_bib0034","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-017-0184-0","article-title":"Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma","volume":"7","author":"Zhang","year":"2017","journal-title":"Cell Biosci."},{"key":"10.1016\/j.neo.2025.101131_bib0035","article-title":"Bromodomain inhibitors: what does the future hold?","volume":"16","author":"Bhattacharya","year":"2018","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.neo.2025.101131_bib0036","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41416-020-01079-x","article-title":"Bromodomain inhibitors a decade later: a promise unfulfilled?","volume":"123","author":"Mita","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.neo.2025.101131_bib0037","article-title":"Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas. Ashpublications.Org M Bisserier, N WajapeyeeBlood","author":"Bisserier","year":"2018","journal-title":"J. Am. Soc. Hematol."},{"key":"10.1016\/j.neo.2025.101131_bib0038","article-title":"Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors","volume":"6","author":"Baker","year":"2025","journal-title":"Oncotarget."},{"key":"10.1016\/j.neo.2025.101131_bib0039","first-page":"1","article-title":"Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4","volume":"10","author":"Calder","year":"2021","journal-title":"Oncog"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625000107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625000107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T23:19:56Z","timestamp":1740784796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558625000107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":39,"alternative-id":["S1476558625000107"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2025.101131","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2Y641mut germinal center-derived lymphoma","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2025.101131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101131"}}